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• Hepatocellular carcinoma (HCC) is a leading cause of 
cancer-related death in world wide.
• TD26 =            tumor size
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Abstract
was highly expressed in HCC tumor
increased lipogenesis in HCC cells











 brown adipose tissues
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TD26








 the most common primary malignancy 
of liver cancer
 sixth most common cancer
 second leading cause of cancer-related 




• Sorafenib is the first-line treatment for advanced HCC
• Sorafenib VEGFR, PDGFR and Raf
• In HCC  patients the responsive rate to sorafenib
remains low.
• oncogenic pathways: , and 
• aberrant lipogenesis cause to cancer
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Introduction
increased lipid biosynthesis has 
been reported to promote HCC
transcriptional master 
regulator 




SREBPs                              helix-loop-helix–leucine zipper
SREBP1
SREBP2
expression genes involved in 


















cell proliferation in varieties of human cancers
activated by the oncogenic AKT-mTORC1 signaling 
pathway
positively correlate with tumor size and tumor-node 
metastasis tumor suppressor AMPK
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samples          56 of primary HCC tumor tissues
were               56  of matched normal tissues 
collected         96 HCC tumor




56 of primary HCC tumor tissues







56 of primary HCC tumor tissues
56  of matched normal tissues
96 HCC tumor samples
Shanghai Eastern Hepatobiliary Surgery Hospital
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DMEM with 10% FBS
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The harvested tumors were:
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Quantitative PCR
Total RNA was extracted using Trizol kit (Invitrogen)




















200 ul isopropanol / methanol supernatant
Triglyceride and cholesterol assays
 Intracellular triglyceride levels were measured using a triglyceride 
assay kit (Nanjing Jiancheng Bioengineering Institute, China)
 Intracellular cholesterols were detected using a cholesterol 








cell lysates were analyzed using the 






lysed in IP lysis buffer (Thermo Fisher, Inc)
protease inhibitor cocktail (Merck Millipore, Germany)
4°C







































TD26 is upregulated in HCC tissues and is a poor prognostic 
marker in HCC
TD26 promotes HCC cell proliferation in vitro
qPCR and western blot assays showed TD26 expression:
in HepG2 & Huh7 
in SMMC-7721 & MHCC-97L cells
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Results
TD26 promotes HCC tumor growth in vivo
TD26 positively correlates with lipogenesis in HCC cells and tissues




TD26 interacts with nSREBP1 to block AMPK
TD26 interacting with nSREBP1 is essential for TD26 mediated 





TD26 is highly expressed in HCC tumor tissues
•TD26 is positively correlated with tumor size
TD26 increases HCC cell proliferation and 




TD26 can negatively regulate NF-kB
•Western blot and ELISA assays showed that 
thesecretory signal peptide is not required 
for TD26 expression but is essential for 
secretion of TD26
These findings indicate that TD26 can function 
intracellularly independent its secretory feature.
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Discussion
Several studies have reported increased TD26 
levels in obesity and/or diabetes patients
•recent study indicates increased TD26 levels 
in cirrhosis patients
diabetes, obesity and cirrhosis are risk factors 
for HCC, it is conceivable that TD26 may play a 
role in HCC development
•SREBP1 should be a promising therapeutic 




we demonstrate that TD26 is a novel positive regulator of 
SREBP1 in HCC by interacting with SREBP1 to compete AMPK.
C-terminal TD26 may play a major role in modulating TD26-mediated 
increase of lipogenesis and cell proliferation in HCC.
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Thank you for attention
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